Neuroprotective agents for the treatment of acute ischemic stroke

Bruce Ovbiagele; Chelsea S. Kidwell; Sidney Starkman; Jeffrey L. Saver

doi:10.1007/s11910-003-0031-z

Neuroprotective agents for the treatment of acute ischemic stroke

Bruce Ovbiagele, Chelsea S. Kidwell, Sidney Starkman, Jeffrey L. Saver

Research output: Contribution to journal › Review article › peer-review

94 Scopus citations

Abstract

Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.

Original language	English (US)
Pages (from-to)	9-20
Number of pages	12
Journal	Current Neurology and Neuroscience Reports
Volume	3
Issue number	1
DOIs	https://doi.org/10.1007/s11910-003-0031-z
State	Published - Jan 2003
Externally published	Yes

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology

Access to Document

10.1007/s11910-003-0031-z

Fingerprint Dive into the research topics of 'Neuroprotective agents for the treatment of acute ischemic stroke'. Together they form a unique fingerprint.

Cite this

@article{89954368379040fead44495c6fcb695e,

title = "Neuroprotective agents for the treatment of acute ischemic stroke",

abstract = "Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.",

author = "Bruce Ovbiagele and Kidwell, {Chelsea S.} and Sidney Starkman and Saver, {Jeffrey L.}",

year = "2003",

month = jan,

doi = "10.1007/s11910-003-0031-z",

language = "English (US)",

volume = "3",

pages = "9--20",

journal = "Current Neurology and Neuroscience Reports",

issn = "1528-4042",

publisher = "Current Medicine Group",

number = "1",

}

TY - JOUR

T1 - Neuroprotective agents for the treatment of acute ischemic stroke

AU - Ovbiagele, Bruce

AU - Kidwell, Chelsea S.

AU - Starkman, Sidney

AU - Saver, Jeffrey L.

PY - 2003/1

Y1 - 2003/1

N2 - Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.

AB - Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.

UR - http://www.scopus.com/inward/record.url?scp=0042888736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042888736&partnerID=8YFLogxK

U2 - 10.1007/s11910-003-0031-z

DO - 10.1007/s11910-003-0031-z

M3 - Review article

C2 - 12507405

AN - SCOPUS:0042888736

VL - 3

SP - 9

EP - 20

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 1

ER -